a

3S Corporation is one of India’s leading stockist, exporter & wholesaler for Anti-cancer drug & Oncology medicines. We even supply & export Sex Enhancement Drugs, Cardiac & Anti Diabetic Medicines. We are a registered wholesaler & exporter for pharmaceutical products licensed by our FDA and Drug Controller in India. Our license number are 20-B/MZ6-23015 & 21-B/ MZ6-23016.

+(91)-(22)-42643060

3scorp.india@gmail.com
Andheri East, Mumbai - 400099, India.

DISCLAIMER

All the pharmaceutical products we offer are prescription drugs and should be used/taken under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug. We are not an online pharmacy . We do not recommend any drug or give medical advice. We only express opinions and provide information. Whether a medication is right for you is a decision between you and the prescribing doctor. Kindly seek medical advice from a registered doctor 0r hospital/Institution before taking any of these medicines.

Monday - Saturday

10.00 - 19.00

+(91)-(22)-42643060

3scorp.india@gmail.com

Andheri East

Mumbai – 400099, India.

Baraclude 0.5MG

  • oral antiviral drug
  • nucleoside analog

    .

Description

Baraclude is an oral antiviral drug used in the treatment of hepatitis B infection. It is also known as Entecavir. BARACLUDE works to reduce the amount of the hepatitis B virus (HBV) in the body, which may improve the condition of your liver.

Detailed Description:

Baraclude (entecavir) is a nucleoside analog with selectiveactivity against hepatitis B virus (HBV). Nucleoside analogsinhibit DNA synthesis in HBV infected cells, reducing viral loadand disease burden in infected patients. In animal studies, longterm administration of the drug was shown to reduce viral load toundetectable levels for 3-5 years.

Baraclude is specifically indicated for the treatment of chronicHBV infection in adults with evidence of active viral replicationand either evidence of persistent elevations in serumaminotransferases (ALT or AST) or histologically activedisease.

Baraclude is supplied as both an oral tablet and an oralsolution. The recommended dose for treatment-naïve adults andadolescents age 16 or older is 0.5 mg once daily on an emptystomach. The recommended dose is increased to 1.0 mg once daily forpatients with a history of hepatitis B viremia receiving lamivudineor with known lamivudine resistance mutations. For patients withrenal impairment (creatine clearance <50 mL/min), dosageadjustment may be necessary.

Additional Information

Side Effects

Pack Size